Clinical Trials
Adaptive DBS reduced falls
A small randomized crossover feasibility trial tested adaptive deep brain stimulation, or DBS that adjusts stimulation to a person’s walking rhythm, in five people with Parkinson’s. The system was feasible and well tolerated, and three participants in a blinded home phase had fewer falls than with continuous stimulation; the study was small, so it mainly supports a larger trial.
Clinical trialLevel: Under evaluationStudy in peopleWhat the study tells us: The system was feasible and well tolerated, and three participants in a blinded home phase had fewer falls than with continuous stimulation; the study was small, so it mainly supports a larger trial.
Limit: An ongoing trial does not prove effectiveness or mean the treatment is available.
Source: pubmed.ncbi.nlm.nih.govDiabetes drugs passed small pilot
A randomized, double-blind pilot study tested sitagliptin and dapagliflozin, two diabetes drugs, in 12 people with Parkinson’s disease or dementia with Lewy bodies. Both drugs were well tolerated over four weeks, with early movement-score signals favoring dapagliflozin, but the trial was too small and short to prove lasting benefit.
Clinical trialLevel: Under evaluationStudy in peopleWhat the study tells us: Both drugs were well tolerated over four weeks, with early movement-score signals favoring dapagliflozin, but the trial was too small and short to prove lasting benefit.
Limit: A promising signal is not yet a validated diagnostic test and cannot guide treatment by itself.
Source: pubmed.ncbi.nlm.nih.gov
Breakthrough Treatments
Safinamide ranked best in review
A network meta-analysis compared add-on medicines used with levodopa for Asian patients with Parkinson’s motor fluctuations. Safinamide 100 mg ranked highest for reducing daily “OFF” time and improving movement scores compared with rasagiline and lower-dose zonisamide in the included trials.
Systematic reviewLevel: Synthesized evidenceCombines multiple studiesWhat the study tells us: Safinamide 100 mg ranked highest for reducing daily “OFF” time and improving movement scores compared with rasagiline and lower-dose zonisamide in the included trials.
Limit: The conclusion depends on the quality and differences among the included studies; it cannot predict an individual outcome.
Source: pubmed.ncbi.nlm.nih.govNew MAO-B blocker looked selective
A lab study reported a new group of reversible MAO-B inhibitors, medicines aimed at an enzyme involved in dopamine breakdown. The strongest compound, PSH18, showed selective MAO-B activity and predicted brain penetration, but it remains preclinical and has not been tested as a patient treatment.
Preclinical researchLevel: EarlyLaboratory or animal modelWhat the study tells us: The strongest compound, PSH18, showed selective MAO-B activity and predicted brain penetration, but it remains preclinical and has not been tested as a patient treatment.
Limit: A promising signal is not yet a validated diagnostic test and cannot guide treatment by itself.
Source: pubmed.ncbi.nlm.nih.gov
Lifestyle Interventions
Prebiotic mix eased constipation
A double-blind randomized trial assigned 72 people with Parkinson’s to short-chain fatty acids, the prebiotic 2-fucosyllactose, or both for six months. The prebiotic and combined groups had lower constipation severity and better patient-reported quality of life, with the strongest results in the combined supplement group.
Clinical trialLevel: Under evaluationStudy in peopleWhat the study tells us: The prebiotic and combined groups had lower constipation severity and better patient-reported quality of life, with the strongest results in the combined supplement group.
Limit: The report does not provide enough context to turn this headline into medical advice.
Source: pubmed.ncbi.nlm.nih.govHome therapy appeared safe
A pilot randomized trial tested a supervised eight-week home physical therapy program for frail people with Parkinson’s and cognitive impairment. All 15 participants completed the planned sessions without recorded adverse events, and early measures suggested possible gains in frailty, function, disease severity, and quality of life.
Clinical trialLevel: Under evaluationStudy in peopleWhat the study tells us: All 15 participants completed the planned sessions without recorded adverse events, and early measures suggested possible gains in frailty, function, disease severity, and quality of life.
Limit: A promising signal is not yet a validated diagnostic test and cannot guide treatment by itself.
Source: pubmed.ncbi.nlm.nih.gov
Emerging Research
Blood lipids flagged Parkinson’s
Researchers profiled blood lipids in 156 people with idiopathic Parkinson’s and 155 cognitively normal controls. A red-blood-cell lipid panel distinguished the groups with an AUC of 0.834 in the discovery cohort, pointing to lipid biology as a possible blood-based detection path that still needs validation.
Observational studyLevel: Association, not causationObserves people or recordsWhat the study tells us: A red-blood-cell lipid panel distinguished the groups with an AUC of 0.834 in the discovery cohort, pointing to lipid biology as a possible blood-based detection path that still needs validation.
Limit: Without randomization, an association may reflect other differences rather than the intervention causing the result.
Source: pubmed.ncbi.nlm.nih.govGBA1 testing needs confirmation
A study of 175 selected Korean patients with Parkinson’s found that some GBA1 results that looked like exon-level deletions on short-read genetic testing were actually recombinant alleles. The finding matters because GBA1 is a Parkinson’s risk gene, and confirmatory testing can prevent misreading a person’s genetic result. Generated daily from public research databases. For informational purposes only — not medical advice.
Research studyLevel: Not stated in reportDesign not statedWhat the study tells us: For informational purposes only — not medical advice.
Limit: Without randomization, an association may reflect other differences rather than the intervention causing the result.
Source: pubmed.ncbi.nlm.nih.gov
This report is for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.